Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE DigiPath, Inc.
LAS VEGAS, June 5, 2014 /PRNewswire/ -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a life sciences company focused on nutra-pharmaceuticals and pathology solutions, is pleased to announce the appointment of Joe Tanner as Executive Chairman of the Board. Mr. Tanner is an executive with 25 years of experience in CEO and COO roles where he was accountable for up to $180 million in annual top-line revenues.
Steve Barbee, CEO of DigiPath, said, "Joe has exhibited strong leadership abilities in domestic and international sales and marketing, creating and operating in compliance with manufacturing quality control systems, raising funds though both convention financial institutions and nontraditional angel investment sources, and managing public relations."
"For over thirty years, I have assisted in turning around underperforming companies and successfully launching startups that specialize in electronic medical hardware and software technology research, development, manufacturing and sales," said Mr. Tanner. "I look forward to bringing my experience to DigiPath."
A U.S. Navy veteran who served over two years in the Vietnam War and former Washington State Senator, Mr. Tanner received his bachelor's degree in Economics from Harvard University, where he graduated magna cum laude and was awarded Kronfield Prize in Economics. He received his Doctor of Jurisprudence from University of Texas School of Law.
About DigiPath, Inc.
DigiPath, Inc., through its subsidiary, DigiPath, Corp., creates and markets innovative and reliable digital pathology solutions that empower private and academic institutions with the ability to create, store, manage, analyze, and correlate data collected through virtual microscopy.
DigiPath, Inc. digital pathology portfolio includes PathScope™, PathCloud™, PathReview™, and PathConsult™ digital platforms to share and store archive tissue images. DigiPath, Inc. is expanding into new lines of business associated with the research, development, licensing and operation of botanical and nutraceutical products and services.
For more information about this announcement or the company, please visit: www.digipath.com.
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events and future financial and operating performance. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company's products, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. An example of such forward looking statements in this press release include statements regarding the Company developing and completing new products and revenue growth. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
David Williams, CFO
©2012 PR Newswire. All Rights Reserved.